Influence of albuminuria on cardiovascular risk in patients with stable coronary artery disease

Circulation

Volumn 116, Issue 23, 2007, Pages 2687-2693

  Solomon, Scott D ^a   Lin, Julie ^a   Solomon, Caren G ^a   Jablonski, Kathleen A ^b   Rice, Madeline Murguia ^b   Steffes, Michael ^c   Domanski, Michael ^d   Hsia, Judith ^b   Gersh, Bernard J ^e   Arnold, J Malcolm O ^f   Rouleau, Jean ^g   Braunwald, Eugene ^a   Pfeffer, Marc A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^e Mayo Clinic   (United States)

^f LONDON HEALTH SCIENCES CENTRE   (Canada)

^g UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Albuminuria; Cardiovascular diseases; Kidney

Indexed keywords

ALBUMIN; PLACEBO; TRANDOLAPRIL;

ADULT; AGED; ALBUMINURIA; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEATH; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HAZARD ASSESSMENT; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT;

AGED; ALBUMINURIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHRONIC DISEASE; CORONARY DISEASE; CREATININE; DEATH; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; INDOLES; KIDNEY DISEASES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SURVIVAL RATE;

EID: 37349052017     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.107.723270     Document Type: Article

References (22)

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296-1305.
2. Beddhu S, Allen-Brady K, Cheung AK, Horne BD, Bair T, Muhlestein JB, Anderson JL. Impact of renal failure on the risk of myocardial infarction and death. Kidney Int. 2002;62:1776-1783.
3. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351:1285-1295.
4. Tonelli M, Jose P, Curhan G, Sacks F, Braunwald E, Pfeffer M; Cholesterol And Recurrent Events (CARE) Trial Investigators. Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial. BMJ. 2006;332:1426.
5. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Halle JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S; HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286:421-426.
6. Jose P, Tomson C, Skali H, Rouleau J, Braunwald E, Arnold JM, Cuddy T, Sussex B, Bernstein V, Pfeffer M, Solomon S. Influence of proteinuria on cardiovascular risk and response to angiotensin-converting enzyme inhibition after myocardial infarction. J Am Coll Cardiol. 2006;47:1725-1727.
7. MacIsaac RJ, Tsalamandris C, Panagiotopoulos S, Smith TJ, McNeil KJ, Jerums G. Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care. 2004;27:195-200.
8. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, Gans RO, Janssen WM, Grobbee DE, de Jong PE; Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002;106:1777-1782.
9. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 2004;65:2309-2320.
10. Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, Pfeffer MA, Rice MM, Rosenberg YD, Rouleau JL; PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004;351:2058-2068.
11. Solomon SD, Rice MM, A Jablonski K, Jose P, Domanski M, Sabatine M, Gersh BJ, Rouleau J, Pfeffer MA, Braunwald E; Prevention of Events with ACE inhibition (PEACE) Investigators. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation. 2006;114:26-31.
12. Jose P, Tomson C, Skali H, Rouleau J, Braunwald E, Arnold JM, Cuddy T, Sussex B, Bernstein V, Pfeffer M, Solomon S. Influence of proteinuria on cardiovascular risk and response to angiotensin-converting enzyme inhibition after myocardial infarction. J Am Coll Cardiol. 2006;47:1725-1727.
13. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med. 2006;354:2473-2483.
14. Mattix HJ, Hsu CY, Shaykevich S, Curhan G. Use of the albumin/creatinine ratio to detect microalbuminuria: implications of sex and race. J Am Soc Nephrol. 2002;13:1034-1039.
15. Connell SJ, Hollis S, Tieszen KL, McMurray JR, Dornan TL. Gender and the clinical usefulness of the albumin: creatinine ratio. Diabet Med. 1994;11:32-36.
16. Warram JH, Gearin G, Laffel L, Krolewski AS. Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio. J Am Soc Nephrol. 1996;7:930-937.
17. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage: the Steno hypothesis. Diabetologia. 1989;32:219-226.
18. Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristianson K, Lederballe-Pedersen O, Nieminen MS, Okin PM, Omvik P, Oparil S, Wedel H, Snapinn SM, Aurup P. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med. 2003;139:901-906.
19. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Halle JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S; HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286:421-426.
20. Zelmanovitz T, Gross JL, Oliveira JR, Paggi A, Tatsch M, Azevedo MJ. The receiver operating characteristics curve in the evaluation of a random urine specimen as a screening test for diabetic nephropathy. Diabetes Care. 1997;20:516-519.
21. Eshoj O, Feldt-Rasmussen B, Larsen ML, Mogensen EF. Comparison of overnight, morning and 24-hour urine collections in the assessment of diabetic microalbuminuria. Diabet Med. 1987;4:531-533.
22. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation. 2004;110:921-927.